ZUMA-7
The trial that moved CAR-T ahead of transplant as second-line treatment for early-relapsing large B-cell lymphoma, with a survival benefit.
EFS median 8.3 vs 2.0 months (HR 0.40); 2-year EFS 41% vs 16%. Primary OS analysis (NEJM 2023): median not reached vs 31.1 months, HR 0.73; 4-year OS 54.6% vs 46.0%. Only 36% of the standard arm reached transplant. Led to April 2022 approval of axi-cel in second line.
- Median 8.3 vs 2 months with Axi-cel compared with Standard care; about 6.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 60 percent lower chance of the event at any given time (hazard ratio 0.4, likely range 0.31 to 0.51).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 54.6 vs 46 out of 100 alive at 4 years with Axi-cel compared with Standard care; 8.6 more per 100.
- Roughly one extra person helped for every 12 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 27 percent lower chance of the event at any given time (hazard ratio 0.73, likely range 0.54 to 0.98).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Large B-cell lymphoma refractory or relapsed within 12 months of frontline therapy: axi-cel vs salvage chemotherapy + autologous transplant. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
359 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival (median)primary | Axi-cel | 180 | 8.3 months | 0.4 (0.31–0.51) | <0.001 | link |
| Standard care | 179 | 2 months | ||||
| Overall survival at 4 years | Axi-cel | — | 54.6% | 0.73 (0.54–0.98) | 0.03 | link |
| Standard care | — | 46% |
TRANSFORM confirmed ZUMA-7's conclusion with a different CD19 CAR-T and a more permissive design that allowed bridging chemotherapy, making the results closer to real-world practice. Liso-cel's low toxicity makes it attractive for older or frailer patients and for outpatient delivery. Together the two trials made CAR-T the standard second-line therapy for early-relapsing aggressive lymphoma.
ZUMA-7 rewrote second-line treatment for aggressive lymphoma: patients whose disease returns within a year of R-CHOP should be offered CAR-T rather than salvage chemotherapy and transplant. It is also one of the few cell-therapy trials to show an overall survival benefit despite crossover. Patients relapsing later than 12 months were not studied and transplant remains standard for them if chemosensitive.
ZUMA-1 showed that CAR-T can cure a meaningful fraction of adults whose aggressive lymphoma no longer responds to chemotherapy, a group with a historical median survival of about six months (SCHOLAR-1). Axi-cel became the first CAR-T approved for lymphoma and later the first to beat standard second-line therapy in ZUMA-7. The comparatively high neurotoxicity of CD28-costimulated products was also first characterised here.
Pages like this
not linked directly; found by shared links- TrialTRANSFORM
Shares Early relapse: CAR-T before transplant, Salvage therapy, Autologous stem cell transplant (ASCT), TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma.
- TrialBELINDA
Shares Early relapse: CAR-T before transplant, TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, Diffuse large B-cell lymphoma.
- TermApheresis (leukapheresis)
Shares Bridging therapy, Autologous stem cell transplant (ASCT), CAR-T cell therapy.
- IdeaHead-to-head bispecific vs CAR-T in second-line LBCL
Shares Axicabtagene ciloleucel, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- TermICANS (neurotoxicity)
Shares TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma, ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, Manufacturing cost and time for living and radioactive medicines.
- IdeaMandatory public reporting of vein-to-vein time and failure rate per CAR-T product
Shares Axicabtagene ciloleucel, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- Key paperJULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma
Shares ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaFull refund for CAR-T if the patient has not responded at three months
Shares Axicabtagene ciloleucel, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.